Esperion Therapeutics (ESPR) has an average broker rating of 2.5, which is interpreted as a Buy, as rated by 10 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 7 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Esperion Therapeutics (ESPR) : The most positive equity analysts on Esperion Therapeutics (ESPR) expects the shares to touch $80, whereas, the least positive believes that the stock will trade at $13 in the short term. The company is covered by 6 Wall Street Brokerage Firms. The average price target for shares are $44 with an expected fluctuation of $24.55 from the mean.
Esperion Therapeutics (NASDAQ:ESPR): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $10.00 and $9.94 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $10.48. The buying momentum continued till the end and the stock did not give up its gains. It closed at $10.28, notching a gain of 1.78% for the day. The total traded volume was 731,473 . The stock had closed at $10.10 on the previous day.
Also, Equity analysts at the Brokerage firm JP Morgan downgrades its rating on Esperion Therapeutics (NASDAQ:ESPR). The rating major has initiated the coverage with neutral rating on the shares. Earlier, the shares were rated a Overweight by the brokerage firm. The Analysts at JP Morgan lowers the price target from $50 per share to $15 per share. The rating by the firm was issued on June 29, 2016. The company shares have dropped -88.55% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $100.98 and the one year low was seen on Jun 29, 2016. The 50-Day Moving Average price is $15.65 and the 200 Day Moving Average price is recorded at $16.62.
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardio-metabolic risk markers. The Companys primary activities include conducting research and development activities, including nonclinical, preclinical and clinical testing, performing business and financial planning, recruiting personnel, and raising capital. ETC-1002, the Companys lead product candidate, is an orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with other LDL-cholesterol lowering therapies currently available. ETC-1002 is being developed for patients with hypercholesterolemia. One completed Phase IIb clinical study and a second that is nearing completion build upon a Phase I and Phase II clinical development program for ETC-1002.